ClinicalTrials.gg
Enrolling by invitationNCT07045701Updated Jul 1, 2025

FMXIN002 in Patients at Risk of Anaphylaxis

A Phase 2/3 interventional study of Epinephrine 4mg nasal powder spray and Adrenalin 0.5mg Injectable Product in Anaphylaxis Food, sponsored by Nasus Pharma. Enrolling by invitation at 1 site in Israel. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Nasus Pharma · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing epinephrine in Anaphylaxis — 3 open to participants now, 3 under way, 1 of them phase 3. Epinephrine · Anaphylaxis.

Planned enrollment
3rd of 11
30 · median 23
Started
2025
with 2 others
Phase 2/3
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
4 of 11
Nasus Pharma

Among the 11 studies testing epinephrine in Anaphylaxis, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 2/3, and was the 9th registered.

Anaphylaxis

101 studies on the registry are indexed under Anaphylaxis; 21 are open to participants now.

Browse Anaphylaxis studies →

Open to participants now

3 of the 11 studies testing epinephrine in Anaphylaxis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About epinephrine

Epinephrine: first FDA approval 1948 (XYLOCAINE W/ EPINEPHRINE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Anaphylaxis studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing epinephrine in Anaphylaxis, or all of them as a file.
02

Study summary

Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis.

Study Design

  • Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more rapidly-than IM epinephrine, as measured by clinical parameters.
Read the detailed description

Study Procedures

  1. Informed Consent: Participants will sign consent forms.
  2. Food Challenge: Subjects will undergo routine diagnostic oral food challenges (OFC) relevant to their suspected allergens.
  3. Assessment: At the first signs of allergic symptoms, a physician will assess the subject.
  4. Treatment Criteria: If a Grade II or III anaphylactic reaction occurs, the participant will receive either:

    A). Intranasal spray of epinephrine FMXIN002 4mg + placebo saline injection B). Intranasal spray of placebo + intramuscular epinephrine injection (Adrenalin 0.5mg)

    One administration will always be epinephrine; the other, placebo.

  5. Randomization: 1:1 between the 2 study arms.
  6. Exclusion from Trial Treatment: Severe reactions or physician discretion may warrant standard care (IM epinephrine 0.5 mg) without study drug.
  7. Blinding: Double-blinded setup with pre-prepared, numbered envelopes containing randomized treatment kits (nasal spray + injection).
  8. Supportive Treatment: All participants will receive antihistamines (Fenistil drops + fexofenadine 180 mg or desloratadine 5 mg). Inhaled bronchodilators (e.g., Ventolin) will be provided for respiratory symptoms as needed.
  9. Monitoring: Assessments at baseline, symptom onset, and at 3, 5, 10, 15, 30, and 90 minutes post-treatment. Vital signs and system-based symptom assessments will be recorded (Appendix 3).
  10. Rescue Therapy: If no improvement in 3-5 minutes, a second IM epinephrine dose (0.5 mg) will be given. Further treatment will follow standard anaphylaxis protocols
  11. Discharge: Participants with symptom resolution by 90 minutes will be discharged.
03

Conditions studied

  • Anaphylaxis Food

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-40 years, any gender
  • Documented or suspected food allergy (based on IgE level or clinical history)
  • Development of Grade II or III reaction during OFC

Exclusion criteria

Exclusion Criteria:

  • Age \<18 or >40
  • Poorly controlled asthma ( \< 80% or frequent symptoms)
  • Active eosinophilic esophagitis
  • Pregnancy or risk of pregnancy
  • Mild (Grade I) or very severe (Grade IV) reactions during OFC
  • Decline to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    FMXIN002 4mg + saline IM

    Epinephrine powder nasal spray together with a placebo IM injection

    Combination Product: Epinephrine 4mg nasal powder spray

  • Active comparator
    Adrenaline 0.5mg IM + placebo nasal spray

    Epinephrine IM injection together with a placebo nasal spray

    Combination Product: Adrenalin 0.5mg Injectable Product

Interventions

  • Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline IM injection

    Also known as: FMXIN002

  • Epinephrine 0.5mg for IM injection. Will be administered together with a placebo nasal powder spray.

06

What researchers measure

Primary outcomes

  1. Skin system anaphylaxis symptoms

    Severity grading system for acute allergic reactions. Skin system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021

    Time frame: 0-90 minutes after drug administration

  2. Mucosal system anaphylaxis symptoms

    Severity grading system for acute allergic reactions, mucosal system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021

    Time frame: 0-90 minutes after drug administration

  3. Gastrointestinal system anaphylaxis symptoms

    Severity grading system for acute allergic reactions, gastrointestinal system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021.

    Time frame: 0-90 minutes after drug administration

  4. Respiratory system anaphylaxis symptoms

    Severity grading system for acute allergic reactions, respiratory system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021.

    Time frame: 0-90 minutes after drug administration

  5. Total anaphylaxis severity score

    Severity grading system for acute allergic reactions, Combined systems, anaphylaxis score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021.

    Time frame: 0-90 minutes after drug administration

  6. Vital signs: Blood pressure

    Systolic and diastolic blood pressure by a blood pressure cuff

    Time frame: 0-90 minutes after drug administration

  7. Vital signs: pulse rate

    heart rate by pulse rate measurement

    Time frame: 0-90 minutes after drug administration

  8. Vital signs: oxygen saturation

    % oxygen saturation measurement using oxygen monitor

    Time frame: 0-90 minutes after drug administration

Secondary outcomes

  1. Need for a second epinephrine dose

    Number of patients needed a second dose, by Adrenalin IM injection

    Time frame: 0-90 minutes after drug administration

  2. Adverse events

    Any treatment-related adverse events

    Time frame: 0-90 minutes after drug administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jul 1, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Jun 12, 2026
CompletionEst.
Jul 12, 2026
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07045701
Lead sponsor
Nasus Pharma
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jun 12, 2025
Primary completion
Jun 12, 2026 (estimated)
Completion
Jul 12, 2026 (estimated)
Last update
Jul 1, 2025

Study contacts

Arnon Elizur, Prof.
principal investigator · Assaf-Harofeh Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epinephrine

Start the discussion